Common use of Authorization of Notes Clause in Contracts

Authorization of Notes. The Company will authorize the issue and sale of (i) $60,000,000 aggregate principal amount of its 4.70% Senior Notes, Series A, due December 1, 2023 (the “Series A Notes”) and (ii) $40,000,000 aggregate principal amount of its 4.93% Senior Notes, Series B, due December 1, 2025 (the “Series B Notes” and, together with the Series A Notes, as amended, restated or otherwise modified from time to time pursuant to Section 17 and including any such notes issued in substitution therefor pursuant to Section 13, the “Notes”). The Series A Notes shall be substantially in the form set out in Schedule 1(a) and the Series B Notes shall be substantially in the form set out in Schedule 1(b). Certain capitalized and other terms used in this Agreement are defined in Schedule A. References to a “Schedule” are references to a Schedule attached to this Agreement unless otherwise specified. References to a “Section” are references to a Section of this Agreement unless otherwise specified.

Authorization of Notes. The Company will authorize the issue and sale of (ia) $60,000,000 205,000,000 aggregate principal amount of its 4.706.28% Senior Notes, Series A, due December 1June 26, 2023 2015 (the “Series A Notes”) and (iib) $40,000,000 145,000,000 aggregate principal amount of its 4.936.72% Senior Notes, Series B, due December 1June 26, 2025 2018 (the “Series B Notes” and, together with ”; the Series A Notes and the Series B Notes being hereinafter collectively referred to as the “Notes”, as amended, restated or otherwise modified from time such term to time pursuant to Section 17 and including include any such notes issued in substitution therefor pursuant to Section 13, the “Notes”). The Series A Notes shall be substantially in the form set out in Schedule 1(a) and Exhibit 1 or Exhibit 2, as the Series B Notes shall be substantially in the form set out in Schedule 1(b)case may be. Certain capitalized and other terms used in this Agreement are defined in Schedule A. References B; and references to a “Schedule” are references or an “Exhibit” are, unless otherwise specified, to a Schedule or an Exhibit attached to this Agreement unless otherwise specified. References to a “Section” are references to a Section of this Agreement unless otherwise specifiedAgreement.

Authorization of Notes. The Company will authorize the issue and sale of (i) $60,000,000 400,000,000 aggregate principal amount of its 4.703.86% Senior Notes, Series A, due December 13, 2023 2025 (the “Series A Notes”) and (ii) $40,000,000 100,000,000 aggregate principal amount of its 4.933.86% Senior Notes, Series B, due December 1January 14, 2025 2026 (the “Series B Notes” and, and together with the Series A Notes, as each may be amended, restated or otherwise modified from time to time pursuant to Section 17 and including any such notes issued in substitution therefor pursuant to Section 13, the “Notes”). The Series A Notes shall be substantially in the form forms set out in Schedule 1(a) and the Series B Notes shall be substantially in the form set out in Schedule 1(b), respectively. Certain capitalized and other terms used in this Agreement are defined in Schedule A. References to a “Schedule” are references to a Schedule attached to this Agreement unless otherwise specified. References to a “Section” are references to a Section of this Agreement unless otherwise specified.

Authorization of Notes. The Company will authorize the issue and sale of (ia) $60,000,000 100,000,000 aggregate principal amount of its 4.706.26% Senior Notes, Series A, due December 1August 3, 2023 2014 (the “Series A Notes”) and (iib) $40,000,000 300,000,000 aggregate principal amount of its 4.936.44% Senior Notes, Series B, due December 1August 3, 2025 2017 (the “Series B Notes” and, together with ”; the Series A Notes and the Series B Notes are hereinafter collectively referred to as the “Notes, as amended, restated or otherwise modified from time ,” such term to time pursuant to Section 17 and including include any such notes issued in substitution therefor pursuant to Section 13, the “Notes”). The Series A Notes shall be substantially in the form set out in Schedule 1(a) Exhibit 1-A and the Series B Notes shall be substantially in the form set out in Schedule 1(b)Exhibit 1-B, respectively. Certain capitalized and other terms used in this Agreement are defined in Schedule A. References B; and references to a “Schedule” are references or an “Exhibit” are, unless otherwise specified, to a Schedule or an Exhibit attached to this Agreement unless otherwise specified. References to a “Section” are references to a Section of this Agreement unless otherwise specifiedAgreement.

Authorization of Notes. The Company will authorize the issue and sale of (ia) $60,000,000 325,000,000 aggregate principal amount of its 4.703.92% Guaranteed Senior Notes, Series A, due December 1May 21, 2023 2025 (the “Series A Notes”) and (iib) $40,000,000 275,000,000 aggregate principal amount of its 4.934.02% Guaranteed Senior Notes, Series B, due December 1May 21, 2025 2027 (the “Series B Notes” and, and together with the Series A Notes, each as amended, restated or otherwise modified from time to time pursuant to Section 17 and including any such notes issued in substitution therefor pursuant to Section 13, the “Notes”). The Series A Notes shall be substantially in the form set out in Schedule 1(a) 1-A and the Series B Notes shall be substantially in the form set out in Schedule 1(b)1-B, respectively. Certain capitalized and other terms used in this Agreement are defined in Schedule A. References to a “Schedule” are references to a Schedule attached to this Agreement unless otherwise specified. References to a “Section” are references to a Section of this Agreement unless otherwise specified.

Authorization of Notes. Section 1.1. The Company will authorize the issue and sale of (i) $60,000,000 175,000,000 aggregate principal amount of its 4.705.43% Senior Notes, Series A, due December 1July 7, 2023 2020 (the “Series A Notes”) and (ii) $40,000,000 125,000,000 aggregate principal amount of its 4.931.00% Senior Discount Notes, Series B, due December 1July 7, 2025 2022 (the “Series B Notes” and, together with ”; the Series A Notes and the Series B Note being hereinafter collectively referred to as (the “Notes”), as amended, restated or otherwise modified from time such term to time pursuant to Section 17 and including include any such notes issued in substitution therefor pursuant to Section 13, the “Notes”). The Series A Notes shall be substantially in the form set out in Schedule 1(a) and the Series B Notes shall be substantially in the form set out in Schedule 1(b)Exhibit 1. Certain capitalized and other terms used in this Agreement are defined in Schedule A. References B; and references to a “Schedule” are references or an “Exhibit” are, unless otherwise specified, to a Schedule or an Exhibit attached to this Agreement unless otherwise specified. References to a “Section” are references to a Section of this Agreement unless otherwise specifiedAgreement.

Authorization of Notes. The Company Issuer will authorize the issue and sale of (i) $60,000,000 75,000,000 aggregate principal amount of its 4.704.10% Senior Guaranteed Notes, Series A, due December 1June 13, 2023 2025 (the “Series A Notes”) and (ii) $40,000,000 100,000,000 aggregate principal amount of its 4.934.27% Senior Guaranteed Notes, Series B, due December 1June 13, 2025 2028 (the “Series B Notes” and, and together with the Series A Notes, as amendedthe “Notes,” such term to include any amendments, restated restatements or otherwise modified modifications from time to time pursuant to Section 17 and including any such notes issued in substitution therefor pursuant to Section 13, the “Notes”). The Series A Notes shall be substantially in the form set out in Schedule 1(a) and the Series B Notes shall be substantially in the form set out in Schedule 1(b)1-A and 1-B, respectively. Certain capitalized and other terms used in this Agreement are defined in Schedule A. References to a “Schedule” are references to a Schedule attached to this Agreement unless otherwise specified. References to a “Section” are references to a Section of this Agreement unless otherwise specified.

Authorization of Notes. The Company will authorize the issue and sale of (i) $60,000,000 174,150,000 aggregate principal amount of its 4.70senior notes, of which, on the First Funding Date, $87,075,000 aggregate principal shall be its 4.91% Series A Senior Notes, Series A, Secured Notes due December 1, 2023 (the “Series A Notes”) and, on the Second Funding Date (and (ii) contemporaneous with the cancellation of the Series A Notes), $40,000,000 174,150,000 aggregate principal amount of shall be its 4.934.96% Series B Senior Notes, Series B, Secured Notes due December 1, 2025 2023 (the “Series B Notes” and, together with the Series A Notes, as amended, restated or otherwise modified from time to time pursuant to Section 17 18 and including any such notes issued in substitution therefor pursuant to Section 1314, the “Notes”). The Series A Notes shall be substantially in the form set out in Schedule 1(a) and the Series B Notes shall be substantially in the form respective forms set out in Schedule 1(b). Exhibit 1-A and Exhibit 1-B. Certain capitalized and other terms used in this Agreement are defined in Schedule A. B. References to a “Schedule” are references or an “Exhibit” are, unless otherwise specified, to a Schedule or an Exhibit attached to this Agreement unless otherwise specifiedAgreement. References to a “Section” are references to a Section of to this Agreement unless otherwise specified.

Authorization of Notes. The Company will authorize the issue and sale of (ia) $60,000,000 50,000,000 aggregate principal amount of its 4.704.23% Senior Guaranteed Notes, Series A, A due December September 1, 2023 2022 (the “Series A Notes”) and (iib) $40,000,000 50,000,000 aggregate principal amount of its 4.934.65% Senior Guaranteed Notes, Series BB due October 13, due December 1, 2025 2027 (the “Series B Notes” and, and together with the Series A Notes, such term to include any such notes as amended, restated or otherwise modified from time to time pursuant to Section 17 and including any such notes issued in substitution therefor pursuant to Section 13, the “Notes”). The Series A Notes shall be substantially in the form set out in Schedule 1(a) and the Series B Notes shall be substantially in the form set out in Schedule 1(b)1-A and Schedule 1-B, respectively. Certain capitalized and other terms used in this Agreement are defined in Schedule A. References to a “Schedule” are references to a Schedule attached to this Agreement unless otherwise specified. References to a “Section” are references to a Section of this Agreement unless otherwise specified.

Authorization of Notes. The Company will authorize has authorized the issue and sale of (i) $60,000,000 100,000,000 aggregate principal amount of its 4.70Senior Notes consisting of (i) $50,000,000 aggregate principal amount of its 5.72% Senior Notes, Series A, due December 1September 30, 2023 2019 (the “Series A Notes”) and (ii) $40,000,000 50,000,000 aggregate principal amount of its 4.935.72% Senior Notes, Series B, due December 1March 30, 2025 2020 (the “Series B Notes” and, together with the Series A Notes, as amendedthe “Notes”, restated or otherwise modified from time such term to time pursuant to Section 17 and including include any such notes issued in substitution therefor pursuant to Section 13, the “Notes”13 of this Agreement). The Series A Notes shall will be substantially in the form set out in Schedule Exhibits 1(a) and the Series B Notes shall be substantially in the form set out in Schedule 1(b), with such changes therefrom, if any, as may be approved by you and the Company. Certain capitalized and other terms used in this Agreement are defined in Schedule A. References B; references to a “Schedule” are references or an “Exhibit” are, unless otherwise specified, to a Schedule or an Exhibit attached to this Agreement unless otherwise specified. References to a “Section” are references to a Section of this Agreement unless otherwise specifiedAgreement.

Authorization of Notes. The Company will authorize the issue and sale of (i) $60,000,000 28,750,000 aggregate principal amount of its 4.704.38% Senior Secured Notes, Series A, due December 1June 15, 2023 2028 (the “Series A Notes”) and (ii) $40,000,000 86,250,000 aggregate principal amount of its 4.934.58% Senior Secured Notes, Series B, due December 1June 15, 2025 2036 (the “Series B Notes” and, together with the Series A Notes, as amended, restated or otherwise modified from time to time pursuant to Section 17 and including any such notes issued in substitution therefor pursuant to Section 13, the “Notes”). The Series A Notes shall be substantially in the form set out in Schedule 1(a) and the Series B Notes shall be substantially in the form set out in Schedule 1(b). Certain capitalized and other terms used in this Agreement are defined in Schedule A. References to a “Schedule” are references to a Schedule attached to this Agreement unless otherwise specified. References to a “Section” are references to a Section of this Agreement unless otherwise specified.

Authorization of Notes. The Company will authorize the issue and sale of (ia) $60,000,000 50,000,000 aggregate principal amount of its 4.706.50% Senior Guaranteed Notes, Series A, due December 1August 7, 2023 2015 (the “Series A Notes”) and (iib) $40,000,000 50,000,000 aggregate principal amount of its 4.937.10% Senior Guaranteed Notes, Series B, due December 1August 7, 2025 2023 (the “Series B Notes” and, together with ”; the Series A Notes and the Series B Notes are hereinafter collectively referred to as the “Notes, as amended, restated or otherwise modified from time ,” such term to time pursuant to Section 17 and including include any such notes issued in substitution therefor pursuant to Section 13, the “Notes”). The Series A Notes shall be substantially in the form set out in Schedule 1(a) Exhibit 1-A and the Series B Notes shall be substantially in the form set out in Schedule 1(b)Exhibit 1-B, respectively. Certain capitalized and other terms used in this Agreement are defined in Schedule A. References B; and references to a “Schedule” are references or an “Exhibit” are, unless otherwise specified, to a Schedule or an Exhibit attached to this Agreement unless otherwise specified. References to a “Section” are references to a Section of this Agreement unless otherwise specifiedAgreement.